Human Papillomavirus (Hpv) Vaccine, 9-Valent

Introduction Overview

Generic Name

human papillomavirus (HPV) vaccine, 9-valent

Brand Name

Gardasil 9

Dosage Form

intramuscular injection

Drug Class

Viral vaccines

Pharmacokinetics

Absorption:
Gardasil 9 is administered as an intramuscular injection, typically into the deltoid muscle of the upper arm or the anterolateral thigh. Following administration, the vaccine antigens are taken up locally by antigen-presenting cells (APCs) within the muscle and nearby lymph nodes. Because Gardasil 9 is composed of virus-like particles (VLPs) and not live viruses, systemic absorption in a traditional pharmacokinetic sense does not apply. Instead, the immune system processes these VLPs to mount a humoral immunologic response. The immune response kinetics typically show rapid development of neutralizing antibodies within weeks after initial immunization.

Distribution:
The vaccine components remain localized at the site of injection and in draining lymph nodes, where they stimulate the adaptive immune response. There is no systemic distribution of live virus because the vaccine is non-infectious. The antigenic proteins do not circulate freely in plasma or tissues but are contained within immune cells. Distribution in the body, therefore, is restricted to the immune system's compartments and lymphatic tissues responsible for antigen presentation and processing.

Metabolism:
Gardasil 9 consists of recombinant HPV L1 proteins assembled as VLPs and an aluminum-based adjuvant. The L1 proteins are not metabolized by enzymatic pathways but are processed by immune cells into peptides that present to T cells. The aluminum adjuvant enhances immune response by creating a depot effect and activating innate immunity but does not undergo classical metabolism. The breakdown products consist of peptides and amino acids processed and recycled via normal protein catabolism pathways.

Elimination:
The vaccine antigens and adjuvant components are eliminated via phagocytosis and degradation within immune cells. Protein fragments and adjuvants are eventually cleared through lymphatic drainage and resorption. There is no renal or hepatic elimination of vaccine components in the conventional pharmacokinetic sense, as the components are not systemically bioavailable. The immune response and generation of memory B cells provide long-lasting protection without the need for drug clearance.

Dosage Forms

Available Dosage Forms:
Gardasil 9 is available as a sterile suspension for intramuscular injection. The vaccine is supplied in single-dose vials or prefilled syringes containing 0.5 mL of suspension. Each 0.5 mL dose contains virus-like particles from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 with an aluminum-containing adjuvant.

Dosages for Adults and Adolescents:
The vaccine is indicated for use in males and females aged 9 through 45 years. For individuals aged 9 through 14 years, a 2-dose schedule is recommended, with the second dose administered 6 to 12 months after the first. For those aged 15 through 45 years and immunocompromised persons, a 3-dose schedule is advised; the second dose is given 1 to 2 months after the first, and the third dose 6 months after the first. The complete series is necessary to induce adequate and long-lasting immunity.

Specific Patient Populations:
Gardasil 9 may be administered to immunocompromised patients, though the immunogenicity may be reduced; therefore, the 3-dose regimen is recommended regardless of age. The vaccine is not approved for use in children under 9 years. Pregnant women are not routinely vaccinated; however, inadvertent administration during pregnancy warrants documentation and monitoring, with no evidence of harm to the fetus. Breastfeeding does not contraindicate administration.

Clinical Guidelines:
The CDC recommends routine vaccination at ages 11 or 12, though vaccination can begin at age 9. Catch-up vaccination is advised through age 26. Vaccination between ages 27 and 45 can be considered based on discussion of benefits and risks. Completion of the full vaccination schedule is critical for optimal protection. Gardasil 9 does not treat existing HPV infections or HPV-associated diseases and does not replace cervical cancer screening or other preventive measures.

Mechanism Of Action

Gardasil 9 functions by stimulating the immune system to recognize and develop immunity against nine types of human papillomavirus (HPV) — types 6, 11, 16, 18, 31, 33, 45, 52, and 58. These HPV types are associated with the majority of cervical cancers, anal cancers, genital warts, and other HPV-related malignancies and lesions. The vaccine contains virus-like particles (VLPs) composed of recombinant L1 major capsid proteins that mimic the native structure of HPV but lack viral DNA, rendering them non-infectious.

Upon intramuscular administration, the VLPs are taken up by antigen-presenting cells (APCs), especially dendritic cells, at the injection site. These APCs process the VLPs and present HPV antigens via major histocompatibility complex (MHC) class II molecules to naïve CD4+ T helper cells, initiating an adaptive immune response. The strong antibody response, predominantly neutralizing immunoglobulin G (IgG), is generated, preventing HPV from infecting epithelial cells upon exposure.

The vaccine-induced neutralizing antibodies bind to the HPV virions, blocking their access to basal epithelial cells, which prevents viral DNA entry and subsequent infection. The robust memory B cell response ensures sustained immunity, providing long-term protection against HPV infection and its associated pathologies. Unlike prophylactic vaccines, Gardasil 9 does not have therapeutic effects on existing HPV infections or lesions.

Compared to earlier HPV vaccines, Gardasil 9 offers broader protection by including five additional oncogenic HPV types (31, 33, 45, 52, and 58) beyond those covered by quadrivalent vaccines, increasing its efficacy in preventing cervical and other HPV-associated cancers. Clinical trials demonstrate significant immunogenicity and safety profiles, reinforcing its role in reducing the global burden of HPV-related diseases.

Pharmacological Actions

Induces active immunity against nine types of human papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52, and 58.
Prevents infection by HPV types associated with cervical, vaginal, vulvar, anal, oropharyngeal, and head and neck cancers.
Provides prophylaxis against genital warts caused by HPV types 6 and 11.
Stimulates production of neutralizing antibodies through antigen presentation and adaptive immune response activation.
Does not contain live virus and is non-infectious, thus cannot cause HPV infection.
Enhances immune memory leading to long-term protective immunity.
Uses virus-like particles (VLPs) to mimic native HPV capsid proteins, eliciting a strong humoral response.
Includes an aluminum-based adjuvant to boost immune response effectiveness.
Triggers antigen processing primarily via dendritic cells and presentation to CD4+ T cells.
Shows no immunosuppressive effects and is safe in immunocompromised individuals, though immune response may be decreased.

Therapeutic Or Clinical Uses

Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
Prevention of vaginal and vulvar cancers associated with HPV infection.
Prevention of anal cancer linked to oncogenic HPV types.
Prophylaxis of genital warts caused by HPV types 6 and 11.
Prevention of oropharyngeal and head and neck cancers caused by high-risk HPV types.
Used in both females and males aged 9 through 45 years for HPV-related disease prevention.
Recommended for routine immunization in preteens (ages 11–12) and catch-up vaccination through age 26.
Administration considered in adults aged 27 to 45 years based on individualized risk assessment.
Reduction of HPV transmission in populations when widely administered.
Complementary to cervical cancer screening programs, not a replacement.
Helps decrease the global burden of HPV-associated cancers and precancerous lesions.

Side Or Adverse Effects

Injection site reactions: pain, swelling, redness, itching, bruising, bleeding, and lump formation.
Common systemic reactions include headache, fever, dizziness, and tiredness post-vaccination.
Gastrointestinal symptoms such as nausea, diarrhea, and stomach pain may occur.
Sore throat and mild upper respiratory symptoms reported in some individuals.
Rare cases of syncope (fainting) have been observed, typically within 15 minutes after vaccination.
Very infrequent seizure-like reactions following vaccination have been documented.
Hypersensitivity reactions, including anaphylaxis and urticaria, are rare but require immediate medical attention.
Injection site pruritus and rash can occur due to immune response or allergic reaction.
Potential transient lymphadenopathy related to immune activation near the injection site.
Extremely low risk of serious adverse events based on large clinical trials and post-marketing surveillance.
No evidence of long-term adverse effects or association with chronic illnesses.
Vaccine is generally well tolerated in immunocompromised patients, with side effects similar to those in immunocompetent individuals.

Precautions

Do not administer to individuals with a known severe allergic reaction to yeast, polysorbate 80, or any component of the vaccine.
Evaluate patients for history of hypersensitivity before vaccination.
Inform patients about the risk of fainting; observe for 15 minutes after injection to prevent injury related to syncope.
Delay vaccination in persons with moderate or severe acute illness until recovery.
Use cautiously in immunocompromised patients as immune response may be reduced.
Women who are pregnant should generally avoid vaccination; if administered inadvertently, document pregnancy and monitor.
Maintain routine cervical cancer screening and HPV testing for vaccinated individuals; the vaccine does not replace these.
Patients with bleeding disorders should be vaccinated with caution; use appropriate techniques to minimize bleeding.
Vaccination does not protect against non-HPV sexually transmitted infections; counsel patients accordingly.
Complete the full vaccine series to ensure adequate protection; incomplete vaccination may result in suboptimal immunity.
Advise patients to report any adverse events following immunization to healthcare providers or surveillance systems.
Avoid simultaneous administration with other vaccines at the same injection site to reduce local adverse effects.

Warnings

Do not administer a booster dose to individuals who have experienced a life-threatening allergic reaction to a previous dose of Gardasil 9.
Risk of syncope and associated injury post-vaccination; recommend observation period of at least 15 minutes after injection.
Seizure-like events have been rarely reported following vaccination; patients with a history of seizures should be observed closely.
Monitor patients for immediate hypersensitivity reactions including anaphylaxis following administration.
Gardasil 9 does not protect against all HPV types, nor does it treat existing HPV infections or HPV-associated diseases.
Vaccination is not a substitute for routine cervical cytology and screening for HPV-related cancers.
Immunization during pregnancy is generally not recommended; risks and benefits should be assessed if exposure occurs.
Individuals with moderate or severe acute illness should defer vaccination until recovery to avoid diagnostic confusion and reduce adverse events.
The vaccine should not be administered intravenously or subcutaneously; improper administration route may affect safety and efficacy.
Risk of local and systemic adverse reactions exists but serious adverse events are extremely rare in large clinical studies.

Contraindication

Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including yeast or polysorbate 80.
History of life-threatening hypersensitivity to a previous dose of Gardasil 9 vaccine.
Known hypersensitivity to any HPV vaccine or any of its excipients.
Administration during pregnancy is contraindicated unless the potential benefits outweigh risks after clinical evaluation.
Should not be administered to children under 9 years of age as safety and efficacy have not been established.
Current moderate or severe acute illness with or without fever; vaccination should be postponed until resolution.
Use caution or avoid in patients with active febrile illness or systemic infections to prevent confounding vaccine reactions.
Contraindicated in patients with a history of allergic reactions to other vaccines containing similar adjuvants or components.

Drug Interactions

No known clinically significant direct drug interactions with other vaccines or medications have been established.
May be administered concomitantly with other vaccines at different injection sites without interference of immunogenicity.
Immunosuppressive therapies such as chemotherapy, corticosteroids, or biologics may attenuate immune response to the vaccine.
No effect on the metabolism or pharmacokinetics of concurrently administered drugs expected, as vaccine components are not systemically bioavailable.
Patients receiving immunosuppressants should complete the full three-dose vaccination schedule for optimal protection.
Concurrent use with live vaccines has not been specifically studied; however, Gardasil 9 is a non-live vaccine and generally safe.
Use caution when co-administering other vaccines with aluminum adjuvants to monitor for increased reactogenicity.
No interaction data indicating alterations in efficacy of Gardasil 9 by antiretroviral drugs in HIV patients.
No evidence that vaccine impacts metabolism of common medications including anticoagulants, antiepileptics, or hormonal therapies.
No known interference with laboratory or diagnostic tests.

Preparations Of The Drug

Gardasil 9 is supplied as a sterile, preservative-free suspension for intramuscular injection.
Available in single-dose 0.5 mL vials or prefilled syringes.
Contains virus-like particles from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 expressed in yeast cells.
Includes aluminum hydroxyphosphate sulfate as adjuvant to enhance immune response.
Formulated without thimerosal or latex components.
Requires refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze.
Discard vial or syringe if frozen or if suspension appears discolored or contains particulate matter.
Administer as a deep intramuscular injection, preferably in the deltoid muscle or anterolateral thigh.
Each dose contains 30 mcg HPV 6 L1 protein, 40 mcg HPV 11 L1 protein, 60 mcg HPV 16 L1 protein, 40 mcg HPV 18 L1 protein, and 20 mcg for each of HPV types 31, 33, 45, 52, and 58.
No preservatives are present; handle under aseptic conditions.
Discard any unused portion after administration due to single-use packaging.